Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on US Healthcare Journal.
Press releases published on April 29, 2025
Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting
GlobeNewswire
·
April 29, 2025
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to …
FibroBiologics Presenting at the ThymUS 2025 Meeting
GlobeNewswire
·
April 29, 2025
HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 240+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic …
Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting
GlobeNewswire
·
April 29, 2025
Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cells TNX-1700 is in preclinical development for gastric and colorectal cancers CHATHAM, N.J., April …
WeightWatchers Streamlines Member Access to Zepbound® Vials with LillyDirect® Pharmacy Provider
GlobeNewswire
·
April 29, 2025
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- WeightWatchers (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”), the global leader in science-backed weight management, today announced a pharmacy integration with Eli Lilly and Company’s LillyDirect® …
Best Legal Steroids for Muscle Growth, Fat Loss, and Strength: Top Natural Alternatives to Anabolic Steroids For Sale (By CrazyBulk)
GlobeNewswire
·
April 29, 2025
New York City, April 29, 2025 (GLOBE NEWSWIRE) -- If you’re serious about building muscle mass, shredding fat, and unlocking peak physical performance — without risking your health — then legal steroid alternatives could be your ultimate game-changer. …
Muscular Dystrophy Association Launches National ALS Awareness Campaign to Accelerate the Search for a Cure
GlobeNewswire
·
April 29, 2025
New York, April 29, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced the launch of its nationwide campaign focused on amyotrophic lateral sclerosis (ALS) during ALS Awareness Month in May, honoring a powerful legacy that …
USA Today Names HealthEquity to its Top 25 Workplaces
GlobeNewswire
·
April 29, 2025
DRAPER, Utah, April 29, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity"), the nation’s largest health savings account (HSA) administrator, today announced it has been named a USA Today Top Workplace for 2025, ranking 23rd …
Four-year Follow-up Data on SPRINT® PNS for Low Back Pain Highlights Sustained Pain Relief Avoiding Costly and Invasive Treatments
GlobeNewswire
·
April 29, 2025
CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE) -- SPR announced the publication of long-term follow-up survey data from a prospective, multicenter study that demonstrated significant and sustained pain relief more than four years after treatment with 60-day …
“Planting the Conversation” for Mental Health Awareness Month
GlobeNewswire
·
April 29, 2025
DALLAS, April 29, 2025 (GLOBE NEWSWIRE) -- As mental health challenges continue to rise in workplaces globally, “Gardenuity for Business,” the B2B wellness solution from Gardenuity, is scaling its efforts to help companies care for their teams. Donna …
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon
GlobeNewswire
·
April 29, 2025
Orchestra BioMed’s Virtue® Sirolimus AngioInfusion Balloon™ (“Virtue SAB”) is the only non-coated drug-eluting balloon system under clinical investigation worldwide and has been awarded multiple FDA Breakthrough Device Designations The Virtue Trial will be …
The International Myeloma Foundation Mourns the Loss of Board Member and Longtime Philanthropist John O’Dwyer
GlobeNewswire
·
April 29, 2025
STUDIO CITY, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Today, the International Myeloma Foundation (IMF) announced with great sadness, the passing of one of the IMF’s Board Members and longtime philanthropist John O’Dwyer, who lived with myeloma for 18 …
Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025
GlobeNewswire
·
April 29, 2025
SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today outlined a framework for a pioneering …
Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer
GlobeNewswire
·
April 29, 2025
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Annamycin is potentially a highly versatile drug capable of working synergistically with numerous mechanistically different FDA approved anticancer first line …
Voom Medical Devices, Inc. Announces $30 Million Debt and Equity Financing
GlobeNewswire
·
April 29, 2025
BRENTWOOD, Tenn., April 29, 2025 (GLOBE NEWSWIRE) -- Voom Medical Devices, Inc. (“Voom” or “the Company”), a leader in minimally invasive orthopedic solutions, today announced the successful closing of a $30 million capital raise through a combination of …
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
GlobeNewswire
·
April 29, 2025
SOUTH SAN FRANCISCO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today …
Vireo Growth Inc. to Release First Quarter 2025 Results on May 9, 2025
GlobeNewswire
·
April 29, 2025
MINNEAPOLIS, April 29, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), today announced that it will release its financial results for its first fiscal quarter ended March 31, 2025 on Friday, May 9, 2025 …
First Major U.S. Commercial Health Insurer Approves Purchase of ReWalk 7 Personal Exoskeleton
GlobeNewswire
·
April 29, 2025
Approval signals important progress in U.S. market expansion as major commercial health insurers begin to follow precedent set with Medicare reimbursement for personal exoskeletons established in 2024 Decision to cover device arrives shortly after the …
CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025
GlobeNewswire
·
April 29, 2025
BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will …
Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025
GlobeNewswire
·
April 29, 2025
CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, presented noteworthy new data at the American Association for Cancer …
LifeMD Announces Plans to Expand Affordable Access to Wegovy® for Cash-Pay Patients
GlobeNewswire
·
April 29, 2025
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announced plans to offer broad, affordable, and streamlined access to Wegovy® (semaglutide) through NovoCare® Pharmacy. This …